2
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
16
Leukemia, Myeloid, Acute
8
Triple Negative Breast Neoplasms
4
Leukemia
3
Cardiotoxicity
2
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Primary Myelofibrosis
1
Primary Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neoplasms, Second Primary
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Liver Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid
1
HER2-negative Breast Cancer
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
1
Biliary Tract Neoplasms
1
Interventions
Drug Therapy
3
Temozolomide
2
Radiotherapy
2
Radiosurgery
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
sacubitril and valsartan sodium hydrate drug combination
1
icotinib
1
dostarlimab
1
beta Carotene
1
avelumab
1
alpha-Tocopherol
1
Varenicline
1
Tyrosine Kinase Inhibitors
1
Trastuzumab
1
Tobacco Use Cessation Devices
1
Therapeutics
1
Thalidomide
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Semen Analysis
1
Registries
1
Probiotics
1
Patient Reported Outcome Measures
1
Panitumumab
1
Nicotine Chewing Gum
1
Myofascial Release Therapy
1
Megestrol Acetate
1
Lenalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Second Primary
×
Anthracyclines
×
Clear all
NCT03199300
2025-12-11
InvestiCAT
University Medical Center Groningen
Active not recruiting
20 enrolled